Psychiatry Excellence Profile picture
May 28 16 tweets 4 min read Read on X
The drug may start the addiction.

But over time, the cue can begin to drive it.

A place. A person. A smell. A mood. A time of day.

This is how the brain learns to seek the drug before the drug is even present. 🧵👇 Image
To understand why, start with what repeated drug use teaches the brain.

The substance is not experienced in isolation.

It happens in a context:

* where the person is
* who they are with
* what they feel
* what they expect
* what their body has learned to anticipate
That context can become a cue.

The brain learns that certain signals predict drug availability.

Over time, the cue stops being background.

It becomes a trigger for craving, attention, motivation, and drug-seeking behaviour.
This is why relapse may not begin at the moment of use.

It may begin earlier.

A cue appears.

Prediction starts.

Attention narrows.

Motivation rises.

Drug-seeking begins.

By the time use occurs, the relapse process may already be underway.
The mechanism is conditioning.

The brain pairs substance use with the signals around it:

* the bar
* the contact
* the argument
* the loneliness
* the payday
* the withdrawal state

The brain learns:

“When this appears, the drug may be near.”
Dopamine helps encode that prediction.

At first, the drug may carry the strongest reward signal.

But with repeated use, dopamine firing can shift earlier.

From the drug itself…

to the cue that predicts it.
That shift is clinically important.

The cue begins to organise:

* attention
* craving
* motivation
* preparation
* drug-seeking behaviour

The patient is not only remembering use.

The brain is preparing for it. Image
In addiction, conditioned cues can produce strong striatal dopamine responses.

In some cases, the dopamine response to the cue may exceed the response to the drug itself.

The signal has shifted.

The cue has become biologically powerful.
This is why “just don’t use” is often too shallow.

The patient may be trying to resist the final step.

But the sequence may have started earlier:

with the cue that activated the seeking system.

Relapse prevention has to move upstream.
Now add habit learning.

Repeated cue-drug pairings can shift behaviour from flexible, goal-directed choice toward more automatic responding.

The question becomes less:

“Do I want this?”

and more:

“This cue means act.”
This is where the striatum becomes important.

Addiction can involve a shift from ventral striatal reward processing toward dorsal striatal habit circuitry.

In practical terms:

drug-seeking becomes less sensitive to consequences…

and more driven by stimulus-response patterns. Image
The prefrontal cortex also matters.

It supports:

* inhibitory control
* decision-making
* emotion regulation
* delayed gratification

But during cue-driven craving, top-down control may struggle against conditioned motivation.

The patient may know the consequence and still feel pulled toward use.Image
The insula adds another layer.

Cues are not only external.

They can be internal:

* tension
* craving
* stress
* withdrawal sensations
* bodily discomfort

The body state itself can become part of the cue network.
So clinically, cue mapping matters.

Ask:

What happens before craving?

Where are they?

Who are they with?

What are they feeling?

What body state appears?

What routine predicts use?

The relapse sequence usually starts before the relapse.
Putting it together:

drug exposure → cue learning → dopamine prediction → craving → narrowed attention → habit circuitry → drug-seeking → relapse risk

The drug may start the learning.

But the cue can later run the sequence.
Relapse prevention cannot start only at the moment of use.

It has to move upstream:

To the cues, predictions, body states, and habits that start the seeking sequence.

To learn more about the neuroscience of addiction and how it translates into clinical practice, click the link below and check out the full course inside The Academy:

psychscene.co/42Yw9hu

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Psychiatry Excellence

Psychiatry Excellence Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @psycheureka

May 25
Psychodynamic psychotherapy is built on 2 core processes.

Take one away, and therapy may not progress.

Here are those 2 processes and how they apply in practice: 🧵👇

(scroll through to see number 2) Image
1/ Attachment

The connection between therapist and patient.

In psychodynamic psychotherapy, it is this therapist-patient bond that forms the foundation of the entire therapeutic process.

Without enough connection, mentalisation has less room to develop. Image
2/ Mentalisation

This refers to how the patient perceives what is going on, both cognitively and emotionally.

It is the patient’s ability to notice and make sense of internal experience as therapy progresses. Image
Read 8 tweets
May 24
Gabapentin and pregabalin are often described as “GABA-like.”

But clinically, that can be misleading.

They do not act by binding to GABA receptors.

To understand their role in psychiatry, let's start with what gabapentinoids actually do. 🧵👇 Image
Despite their structural similarity to GABA, gabapentin and pregabalin do not bind to GABA-A or GABA-B receptors.

Their main target is the α2δ subunit, especially α2δ-1, of voltage-gated calcium channels.
By acting at α2δ subunits on presynaptic neurons, gabapentinoids reduce calcium-channel-mediated neurotransmitter release.

This can reduce release of excitatory neurotransmitters such as:

* glutamate
* substance P
* noradrenaline

So the effect is not “more GABA.”

It is reduced excitatory signalling.Image
Read 13 tweets
May 18
Psychiatric disorders are not explained by genetic vulnerability alone.

Stress, trauma, substance use, nutrition, infection, and medication can also shape gene expression.

That is where epigenetics becomes clinically relevant. 🧵👇 Image
Let’s start with the definition.

Epigenetics refers to changes in gene activity and expression that occur without changing the DNA sequence itself.

The genetic code may stay the same.

But how that code is read can change. Image
That matters because gene expression is dynamic.

Environmental exposures can influence whether certain genes become more or less active.

Relevant factors may include:

* chronic stress
* trauma
* nutrition
* infection
* medication
* substance use
Read 15 tweets
May 11
Methylphenidate is not simply “a stimulant.”

Its clinical effect depends on how dopamine and noradrenaline are increased, released, sustained, and worn off.

That is where formulation choice becomes clinically important. 🧵👇 Image
Methylphenidate blocks the reuptake of:

* dopamine via DAT
* noradrenaline via NAT

This increases dopamine and noradrenaline in the synaptic cleft, supporting dopaminergic and noradrenergic transmission.
That matters because dopamine and noradrenaline are central to ADHD-relevant circuits.

Methylphenidate increases dopamine and noradrenaline in the:

* striatum
* prefrontal cortex

These systems help regulate attention, inhibition, and executive control.
Read 15 tweets
May 9
It’s not just: 

“Is psychosis improving?”

It’s also:

“Is the patient returning to daily life?”

Clinical care often focuses on reducing psychosis.

But recovery also means rebuilding function. 🧵👇 Image
This is the recovery gap in schizophrenia.

Positive symptoms may improve:

* hallucinations
* delusions
* thought disorder

But the patient may still struggle with motivation, expression, social connection, and goal-directed behaviour.
Functional recovery depends on capacities that are easy to overlook:

Can the patient initiate?

Can they connect?

Can they communicate emotion?

Can they pursue goals?

Can they sustain a daily routine?

These are not secondary details.
Read 15 tweets
May 8
Depression is not one biological pathway.

For some patients, monoamines may be only part of the story.

Here’s how new developments in the biology of depression are reshaping antidepressant treatment: 🧵👇 Image
For decades, antidepressants have largely targeted monoamine systems:

* serotonin
* noradrenaline
* dopamine

This model changed depression care.

But it also left major gaps:

* delayed onset
* treatment resistance
* tolerability problems
* incomplete response
The problem is not that monoamines are “wrong.”

It is that depression is biologically heterogeneous.

Different patients may have symptoms shaped by different systems:

* glutamate
* inflammation
* stress biology
* reward circuitry
* gut-brain signalling
Read 14 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(